Observation is effective in the management of haemangioma of infancy.

Article

Using a combination of observation and amblyopia therapy is successful in mild cases of periocular haemangioma of infancy (HOI).

An investigation published in the Journal of Paediatric Ophthalmology and Strabismus has demonstrated that using a combination of observation and amblyopia therapy is successful in mild cases of periocular haemangioma of infancy (HOI).

Dr Assad Jalil et al., Manchester Royal Eye Hospital, Manchester, UK, conducted a retrospective study on 41 children. The children were divided into groups according to treatment methods. This included observation, intralesional steroid injections (ILSI), and oral steroids.

Of the children included in the research, 24 had amblyopia at presentation, 18 children were in the observation group, 17 were administered ILSI and 6 children were given oral steroids.

Success was measured when HOI regression was completed before the child was 5 years of age (cosmetic group), astigmatism was reduced by 1 dioptre cylinder (DC) (astigmatism group) or if there was no evidence of amblyopia at the last follow-up (visual axis obscuration group).

The cosmetic group demonstrated a high success rate, with all but 2 patients treated. The visual axis obscuration group saw 6 of 7 patients treated.

Mean astigmatic correction of the patients was 1.65 ± 1.34 DC pre-treatment and 0.91 ± 1.17 DC post-treatment. This proved to be statistically significant and proved that, as well as observation, ILSI and oral steroids can be effective for treating lesions. However, their role has not been completely determined with regards to spontaneously resolving lesions.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.